Cadrenal Therapeutics (CVKD)

FY2023 Reported With Continued Progress Toward The Phase 3 Tecarfarin Trial


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
March 13, 2024
Report ID: 26590
Already Registered?
Click the Get Report button to login and view the full report, with price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Register Now to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc.
Healthcare
Biotechnology
Ticker
CVKD
Current Price
$12.55 -6.13%
Market Cap
$20.8M
Price Target
Refer to Report
Volume
69.5K
52wk Range
$5.4 - $32.55
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.